ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1191

The Risk of Major Adverse Cardiovascular Events in Patients with Systemic Sclerosis: A Population-Based, Matched Cohort Study

HSIN-HUA CHEN1 and Tsai-Hung Yen2, 1Taichung Veterans General Hospital, Taichung, Taiwan, 2Division of General Medicine, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan

Meeting: ACR Convergence 2022

Keywords: Epidemiology, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: The pathologic hallmarks of systemic sclerosis (SSc) included a non-inflammatory obliterative vasculopathy affecting small arteries and arterioles in multiple vascular beds. Whether macrovascular involvement was more prevalent in patients with SSc was still controversial. Therefore, we conducted a nationwide, population-based cohort study to assess the risk of major adverse cardiovascular events (MACE) in incident SSc patients.

Methods: Claim data from the 1997–2013 Taiwanese National Health Insurance Research Database was used to identify newly diagnosed SSc patients from 2001 to 2013. We selected age, sex and year of index date-matched (1:20) non-SSc individuals from claim data of one million representative individuals enrolled in 2000 (LHID2000) in Taiwan. Therefore, 1,611 SSc patients and 32,220 non-SSc individuals were included. From this age-sex matched population, we further selected SSc patients and non-SSc individuals via propensity-score (PS) matching (1:2) for age, sex, and selected comorbidities confounders using the greedy algorithm. Ultimately, we identified 1,379 SSc patients and 2,758 PSM-matched non-SSc individuals, with balanced baseline characteristics between groups. The primary outcome was MACE which was composed of myocardial infarction, ischemic stroke and patients undergoing percutaneous coronary intervention or coronary artery bypass graft. We calculated the incidences of MACE of both groups in the PSM population and estimated the association between SSc and the risk of MACE using a time-dependent conditional Cox regression models adjusting for level of urbanization of residence, low income, a history of MACE and concomitant medications including use of aspirin, clopidogrel, dipyridamole and warfarin shown as adjusted hazard ratios (aHR) with 95% confidence intervals (CI).

Results: During the mean follow-up of 5.23 and 6.20 years in SSc patients and non-SSc individuals,
the incidence rates of MACE were not significantly different between groups (1,012 vs 882 cases per 105 person-years, incidence rate ratio (IRR), 1.15; 95% CI, 0.87–1.52, p = 0.337). However, SSc patients had a higher incidence of myocardial infarction (IRR, 1.76; 95% CI, 1.08-2.86) but not ischemic stroke (IRR, 0.89, 95%CI 0.61-1.29). Using the crude and adjusted time-dependent conditional Cox regression analyses, SSc was not associated with the risk of MACE (crude HR, 1.28, 95% CI, 0.91–1.82; aHR, 0.88; 95% CI, 0.49–1.58) Other predictors for MACE included a history of MACE (HR, 2.62; 95% CI, 1.08-2.86), use of clopidogrel (aHR, 19.72; 95% CI, 6.77–57.42), use of aspirin (aHR, 9.41; 95%, CI 4.43–19.99) and use of warfarin (aHR 3.91, 95% CI 1.11–13.72).

Conclusion: This nationwide, population-based cohort study did not reveal and increased risk of MACE in incident SSc patients. However, the incidence of myocardial infarction was significantly higher in SSc patients compared with PS-matched non-SSc individuals.

Supporting image 1

Table. Incidences of MACE in SSc patients and non-SSc individuals


Disclosures: H. CHEN, None; T. Yen, None.

To cite this abstract in AMA style:

CHEN H, Yen T. The Risk of Major Adverse Cardiovascular Events in Patients with Systemic Sclerosis: A Population-Based, Matched Cohort Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-risk-of-major-adverse-cardiovascular-events-in-patients-with-systemic-sclerosis-a-population-based-matched-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-risk-of-major-adverse-cardiovascular-events-in-patients-with-systemic-sclerosis-a-population-based-matched-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology